Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates

Melissa M. Haulcomb, Nichole A. Mesnard-Hoaglin, Richard J. Batka, Rena M. Meadows, Whitney M. Miller, Kathryn P. Mcmillan, Todd J. Brown, Virginia M. Sanders, Kathryn Jones

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Disease progression rates among patients with amyotrophic lateral sclerosis (ALS) vary greatly. Although the majority of affected individuals survive 3-5 years following diagnosis, some subgroups experience a more rapidly progressing form, surviving less than 1 year, and other subgroups experience slowly progressing forms, surviving nearly 50 years. Genetic heterogeneity and environmental factors pose significant barriers in investigating patient progression rates. Similar to the case for humans, variation in survival within the mSOD1 mouse has been well documented, but different progression rates have not been investigated. The present study identifies two subgroups of B6SJL mSOD1G93A mice with different disease progression rates, a fast progression group (FPG) and slow progression group, as evidenced by differences in the rate of motor function decline. In addition, increased disease-associated gene expression within the FPG facial motor nucleus confirmed the presence of a more severe phenotype. We hypothesize that a more severe disease phenotype could be the result of 1) an earlier onset of axonal disconnection with a consistent degeneration rate or 2) a more severe or accelerated degenerative process. We performed a facial nerve transection axotomy in both mSOD1 subgroups prior to disease onset as a method to standardize the axonal disconnection. Instead of leading to comparable gene expression in both subgroups, this standardization did not eliminate the severe phenotype in the FPG facial nucleus, suggesting that the FPG phenotype is the result of a more severe or accelerated degenerative process. We theorize that these mSOD1 subgroups are representative of the rapid and slow disease phenotypes often experienced in ALS.

Original languageEnglish (US)
Pages (from-to)2752-2768
Number of pages17
JournalJournal of Comparative Neurology
Volume523
Issue number18
DOIs
StatePublished - Dec 15 2015

Fingerprint

Disease Progression
Phenotype
Amyotrophic Lateral Sclerosis
Gene Expression
Axotomy
Genetic Heterogeneity
Facial Nerve
Survival
Facial Nucleus

Keywords

  • ALS
  • Disease progression
  • Facial nerve axotomy
  • Gene expression
  • MN
  • Motoneuron
  • MSOD1

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Haulcomb, M. M., Mesnard-Hoaglin, N. A., Batka, R. J., Meadows, R. M., Miller, W. M., Mcmillan, K. P., ... Jones, K. (2015). Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates. Journal of Comparative Neurology, 523(18), 2752-2768. https://doi.org/10.1002/cne.23814

Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates. / Haulcomb, Melissa M.; Mesnard-Hoaglin, Nichole A.; Batka, Richard J.; Meadows, Rena M.; Miller, Whitney M.; Mcmillan, Kathryn P.; Brown, Todd J.; Sanders, Virginia M.; Jones, Kathryn.

In: Journal of Comparative Neurology, Vol. 523, No. 18, 15.12.2015, p. 2752-2768.

Research output: Contribution to journalArticle

Haulcomb, MM, Mesnard-Hoaglin, NA, Batka, RJ, Meadows, RM, Miller, WM, Mcmillan, KP, Brown, TJ, Sanders, VM & Jones, K 2015, 'Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates', Journal of Comparative Neurology, vol. 523, no. 18, pp. 2752-2768. https://doi.org/10.1002/cne.23814
Haulcomb MM, Mesnard-Hoaglin NA, Batka RJ, Meadows RM, Miller WM, Mcmillan KP et al. Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates. Journal of Comparative Neurology. 2015 Dec 15;523(18):2752-2768. https://doi.org/10.1002/cne.23814
Haulcomb, Melissa M. ; Mesnard-Hoaglin, Nichole A. ; Batka, Richard J. ; Meadows, Rena M. ; Miller, Whitney M. ; Mcmillan, Kathryn P. ; Brown, Todd J. ; Sanders, Virginia M. ; Jones, Kathryn. / Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates. In: Journal of Comparative Neurology. 2015 ; Vol. 523, No. 18. pp. 2752-2768.
@article{b133b5c0a5904cf0bb9ee3c654ba98c2,
title = "Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates",
abstract = "Disease progression rates among patients with amyotrophic lateral sclerosis (ALS) vary greatly. Although the majority of affected individuals survive 3-5 years following diagnosis, some subgroups experience a more rapidly progressing form, surviving less than 1 year, and other subgroups experience slowly progressing forms, surviving nearly 50 years. Genetic heterogeneity and environmental factors pose significant barriers in investigating patient progression rates. Similar to the case for humans, variation in survival within the mSOD1 mouse has been well documented, but different progression rates have not been investigated. The present study identifies two subgroups of B6SJL mSOD1G93A mice with different disease progression rates, a fast progression group (FPG) and slow progression group, as evidenced by differences in the rate of motor function decline. In addition, increased disease-associated gene expression within the FPG facial motor nucleus confirmed the presence of a more severe phenotype. We hypothesize that a more severe disease phenotype could be the result of 1) an earlier onset of axonal disconnection with a consistent degeneration rate or 2) a more severe or accelerated degenerative process. We performed a facial nerve transection axotomy in both mSOD1 subgroups prior to disease onset as a method to standardize the axonal disconnection. Instead of leading to comparable gene expression in both subgroups, this standardization did not eliminate the severe phenotype in the FPG facial nucleus, suggesting that the FPG phenotype is the result of a more severe or accelerated degenerative process. We theorize that these mSOD1 subgroups are representative of the rapid and slow disease phenotypes often experienced in ALS.",
keywords = "ALS, Disease progression, Facial nerve axotomy, Gene expression, MN, Motoneuron, MSOD1",
author = "Haulcomb, {Melissa M.} and Mesnard-Hoaglin, {Nichole A.} and Batka, {Richard J.} and Meadows, {Rena M.} and Miller, {Whitney M.} and Mcmillan, {Kathryn P.} and Brown, {Todd J.} and Sanders, {Virginia M.} and Kathryn Jones",
year = "2015",
month = "12",
day = "15",
doi = "10.1002/cne.23814",
language = "English (US)",
volume = "523",
pages = "2752--2768",
journal = "Journal of Comparative Neurology",
issn = "0021-9967",
publisher = "Wiley-Liss Inc.",
number = "18",

}

TY - JOUR

T1 - Identification of B6SJL mSOD1G93A mouse subgroups with different disease progression rates

AU - Haulcomb, Melissa M.

AU - Mesnard-Hoaglin, Nichole A.

AU - Batka, Richard J.

AU - Meadows, Rena M.

AU - Miller, Whitney M.

AU - Mcmillan, Kathryn P.

AU - Brown, Todd J.

AU - Sanders, Virginia M.

AU - Jones, Kathryn

PY - 2015/12/15

Y1 - 2015/12/15

N2 - Disease progression rates among patients with amyotrophic lateral sclerosis (ALS) vary greatly. Although the majority of affected individuals survive 3-5 years following diagnosis, some subgroups experience a more rapidly progressing form, surviving less than 1 year, and other subgroups experience slowly progressing forms, surviving nearly 50 years. Genetic heterogeneity and environmental factors pose significant barriers in investigating patient progression rates. Similar to the case for humans, variation in survival within the mSOD1 mouse has been well documented, but different progression rates have not been investigated. The present study identifies two subgroups of B6SJL mSOD1G93A mice with different disease progression rates, a fast progression group (FPG) and slow progression group, as evidenced by differences in the rate of motor function decline. In addition, increased disease-associated gene expression within the FPG facial motor nucleus confirmed the presence of a more severe phenotype. We hypothesize that a more severe disease phenotype could be the result of 1) an earlier onset of axonal disconnection with a consistent degeneration rate or 2) a more severe or accelerated degenerative process. We performed a facial nerve transection axotomy in both mSOD1 subgroups prior to disease onset as a method to standardize the axonal disconnection. Instead of leading to comparable gene expression in both subgroups, this standardization did not eliminate the severe phenotype in the FPG facial nucleus, suggesting that the FPG phenotype is the result of a more severe or accelerated degenerative process. We theorize that these mSOD1 subgroups are representative of the rapid and slow disease phenotypes often experienced in ALS.

AB - Disease progression rates among patients with amyotrophic lateral sclerosis (ALS) vary greatly. Although the majority of affected individuals survive 3-5 years following diagnosis, some subgroups experience a more rapidly progressing form, surviving less than 1 year, and other subgroups experience slowly progressing forms, surviving nearly 50 years. Genetic heterogeneity and environmental factors pose significant barriers in investigating patient progression rates. Similar to the case for humans, variation in survival within the mSOD1 mouse has been well documented, but different progression rates have not been investigated. The present study identifies two subgroups of B6SJL mSOD1G93A mice with different disease progression rates, a fast progression group (FPG) and slow progression group, as evidenced by differences in the rate of motor function decline. In addition, increased disease-associated gene expression within the FPG facial motor nucleus confirmed the presence of a more severe phenotype. We hypothesize that a more severe disease phenotype could be the result of 1) an earlier onset of axonal disconnection with a consistent degeneration rate or 2) a more severe or accelerated degenerative process. We performed a facial nerve transection axotomy in both mSOD1 subgroups prior to disease onset as a method to standardize the axonal disconnection. Instead of leading to comparable gene expression in both subgroups, this standardization did not eliminate the severe phenotype in the FPG facial nucleus, suggesting that the FPG phenotype is the result of a more severe or accelerated degenerative process. We theorize that these mSOD1 subgroups are representative of the rapid and slow disease phenotypes often experienced in ALS.

KW - ALS

KW - Disease progression

KW - Facial nerve axotomy

KW - Gene expression

KW - MN

KW - Motoneuron

KW - MSOD1

UR - http://www.scopus.com/inward/record.url?scp=84944275887&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944275887&partnerID=8YFLogxK

U2 - 10.1002/cne.23814

DO - 10.1002/cne.23814

M3 - Article

C2 - 26010802

AN - SCOPUS:84944275887

VL - 523

SP - 2752

EP - 2768

JO - Journal of Comparative Neurology

JF - Journal of Comparative Neurology

SN - 0021-9967

IS - 18

ER -